Calls
Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-05 · generated 2026-07-24.
Latest call digest
Pfizer Inc., Q1 2026 Earnings Call, May 05, 2026 · 2026-05-05T14:00:00
Q1 2026 call — May 5, 2026. Pfizer opened the year ahead of its own plan: revenues of $14.5 billion (+2% operationally, ~7% ex-COVID), reported EPS of $0.47 and adjusted EPS of $0.75, both above expectations. Management framed the quarter around two legal developments rather than the print itself — the Vyndamax (tafamidis) patent settlement pushing that LOE out roughly 2.5 years to mid-2031, and a Belgian court ruling on the EU Comirnaty contracts. Together these underpin a restated claim of a high single-digit five-year revenue CAGR beginning in 2029 and improved post-2028 cash flow. Prepared remarks leaned heavily on the oncology pipeline (Padcev EV-304 in muscle-invasive bladder cancer, Elrexfio MagnetisMM-5, atirmociclib), the newly closed Metsera obesity platform, a first-disclosed 35-serotype next-gen adult pneumococcal candidate, and AI across R&D and commercial.
The Q&A reality was more skeptical. Despite the beat, CFO Dave Denton declined to raise full-year guidance, invoking his standard practice of not adjusting after Q1 and the back-half weighting of COVID — conceding that 'absent that, we probably would be raising guidance.' Analysts pressed hardest on capital allocation: whether the Vyndamax clarity opens the door to larger M&A (and what that means for the dividend), when buybacks return, and how the pipeline bridges the stacked 2026-2028 LOEs. Management held the line that the dividend is preserved, that share repurchase moves 'back into greater consideration' but is not imminent, and that a transformative merger is 'not right now very high in our list.' Guidance was reaffirmed, not raised.
Participant coverage from the latest call.
| Group | Participants | Count |
|---|---|---|
| Management | Operator; Francesca DeMartino — Chief Investor Relations Officer, Pfizer Inc.; Albert Bourla — Chairman of the Board & CEO, Pfizer Inc.; David Denton — Executive VP & CFO, Pfizer Inc.; Chris Boshoff — Chief Scientific Officer and President of Research & Development, Pfizer Inc.; Alexandre de Germay — Executive VP & Chief International Commercial Officer, Pfizer Inc.; Aamir Malik — Executive VP & Chief U.S. Commercial Officer, Pfizer Inc. | 7 |
| Analysts | Vamil Divan — MD of Healthcare Research & Senior Equity Research Analyst, Guggenheim Securities, LLC, Research Division; David Risinger — Senior Research Analyst & Senior MD of Biopharma, Leerink Partners LLC, Research Division; Christopher Schott — Senior Analyst, JPMorgan Chase & Co, Research Division; Kerry Holford — Analyst, Joh. Berenberg, Gossler & Co. KG, Research Division; Umer Raffat — Senior MD & Senior Analyst of Equity Research, Evercore ISI Institutional Equities, Research Division; Asad Haider — MD & Senior Healthcare Strategist, Goldman Sachs Group, Inc., Research Division; Evan Seigerman — MD & Senior BioPharma Research Analyst, BMO Capital Markets Equity Research; Courtney Breen — Senior Research Analyst, Bernstein Institutional Services LLC, Research Division; Louise Chen — Research Analyst, Scotiabank Global Banking and Markets, Research Division | 9 |
Curated latest-call exchanges; one row per analyst topic.
| Analyst | Firm | Topic | What changed in Q&A |
|---|---|---|---|
| Chris Schott | JPMorgan | Guidance not raised; BD appetite | Asked why a strong start did not lift guidance and whether Vyndamax clarity enables larger deals; Denton cited COVID back-half seasonality and said absent that they would be raising, and kept BD framed around $7B capacity. |
| Umer Raffat | Evercore ISI | Dividend integrity vs transformative M&A | Probed the odds of a large, dividend-threatening deal and how Bourla and the Board view his tenure and dividend continuity; Bourla said a mega-merger is not a near-term priority given the AI-transformation focus. |
| Asad Haider | Goldman Sachs | Bridging the LOE gap to 2029 growth | Pressed on levers to hit high single-digit CAGR against stacked LOEs and base-business assumptions; Bourla leaned on risk-adjusted pipeline breadth and launched/acquired products growing 22%. |
| Evan Seigerman | BMO Capital Markets | Share repurchases | Asked what else is needed to start buying back stock at current levels; Denton said repurchases move back into greater consideration but the current priority remains R&D and BD investment. |
| Kerry Holford | Berenberg | Comirnaty ex-US and Belgian ruling | Asked about EU vaccination rates and the read-through of the April 2026 Belgian judgment; management said the Q1 Comirnaty decline reflected a lapsed UK contract, not vaccination trends, and work has begun with Poland and Romania to execute the ruling. |
| David Risinger | Leerink Partners | Oncology readouts and org restructuring | Asked about SV and mevrometostat pivotal readouts and the reorganization of BD and strategy; Bourla detailed moving BD under R&D and executive-team reductions, Boshoff framed the mid-year oncology readouts. |
| Vamil Divan | Guggenheim Securities | ADA obesity data expectations | Asked what Pfizer will present at ADA; Boshoff detailed VESPER-1/2/3 disclosures and said amylin monotherapy data comes in the second half. |
| Courtney Breen | Bernstein | Sigvotatug vedotin frontline positioning | Asked how the planned first-line all-comers SV study is positioned versus Symbiotic-Lung-01; Boshoff pointed to the PD-L1-high combination signal and mid-year second-line readout. |
Theme tracker
Themes are curator-classified across supplied calls.
| Theme | Status | Quarters mentioned | Read-through |
|---|---|---|---|
| COVID revenue decline and guidance derisking | persisted | Q2 2023, Q3 2023, Q4 2023, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | COVID has been the dominant swing factor across the entire window — from the 2023 credibility episode through repeated 'derisking' of back-half seasonality. By Q1 2026 it is a smaller, ex-COVID ~7% growth story, but management still cites COVID seasonality as the reason not to raise. |
| Cost realignment and productivity savings | persisted | Q3 2023, Q4 2023, Q3 2024, Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, Q1 2026 | The savings target has been steadily enlarged — $3.5B launched in Q3 2023, then $4B, $4.5B, and by 2025 an aggregate ~$7.2B net cost target plus a separate $1.5B manufacturing program. A consistent, on-track message every quarter. |
| LOE cliff (2026-2028) and post-2028 CAGR | persisted | Q4 2024, Q1 2025, Q3 2025, Q4 2025, Q1 2026 | The patent-cliff transition is the central strategic frame. The Q1 2026 Vyndamax settlement materially reshaped it, extending a $6B+ product and letting management restate a high single-digit five-year CAGR from 2029. |
| Obesity / metabolic strategy | emerged | Q1 2025, Q3 2025, Q4 2025, Q1 2026 | Moved from setback to centerpiece: danuglipron was discontinued in Q1 2025, then the ~$4.9B Metsera acquisition (announced Q3 2025, contested by Novo, closed by Q4 2025) made obesity a lead growth pillar, with VESPER data and a China GLP-1 launch by Q1 2026. |
| Oncology / Seagen ADC platform | persisted | Q2 2024, Q4 2025, Q1 2026 | Consistently positioned as the most advanced growth engine; roughly half of 2026 key readouts are oncology. Candor has crept in — management conceded on the Q4 2025 call that no ADC has beaten docetaxel in second-line lung, a readout still pending. |
| Capital allocation, BD discipline and the dividend | persisted | Q3 2024, Q4 2024, Q1 2025, Q4 2025, Q1 2026 | Sharpened by Starboard's involvement in late 2024, this recurs as questions on BD capacity (which swung from ~$13B to ~$7B post-Metsera), buyback timing and dividend safety. Management's answer is unchanged: dividend preserved, buybacks deferred, tuck-in-biased BD. |
| Trade, tariffs and MFN drug pricing | emerged | Q1 2025, Q2 2025, Q3 2025 | Policy risk dominated the 2025 calls — the Section 232 probe, the July 2025 Trump MFN letter, and a US-government agreement with a three-year tariff grace period reached in Q3 2025. It receded from the Q4 2025 and Q1 2026 discussions once a deal framework was in place. |
| AI across R&D, commercial and manufacturing | emerged | Q4 2025, Q1 2026 | A newer emphasis: Q4 2025 disclosed scaling to more than 1,200 GPUs, and Q1 2026 elevated AI to a headline strategic priority for compressing R&D timelines. |
Guidance ledger
Quotes, calls, and speakers are source-verified; outcomes are curator-classified.
| Verbatim guidance | Call | Speaker | Curator outcome | Outcome note |
|---|---|---|---|---|
| “We continue to expect total company revenues in the range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share in the range of $2.80 to $3 a share.” | Pfizer Inc., Q1 2026 Earnings Call, May 05, 2026 · 2026-05-05T14:00:00 | David Denton | pending | FY2026 guidance reaffirmed, not raised, despite a Q1 beat; full-year result not yet in the supplied call history. |
| “We expect total company full year '26 revenues to be in the range of $59.5 billion to $62.5 billion and full year '26 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share” | Pfizer Inc., Q4 2025 Earnings Call, Feb 03, 2026 · 2026-02-03T15:00:00 | David Denton | pending | Initial FY2026 guide, set alongside a FY2025 result of $62.6B revenue and $3.22 adjusted EPS; 2026 outcome not yet in the supplied history. |
| “we are raising and narrowing our full year 2025 adjusted diluted earnings per share guidance by approximately $0.08 at the midpoint to $3 a share to $3.15 a share.” | Pfizer Inc., Q3 2025 Earnings Call, Nov 04, 2025 · 2025-11-04T15:00:00 | David Denton | kept | FY2025 adjusted EPS finished at $3.22 per the Q4 2025 call, above this raised range. |
| “our revised full year '25 adjusted diluted earnings per share range is now $2.90 to $3.10 a share.” | Pfizer Inc., Q2 2025 Earnings Call, Aug 05, 2025 · 2025-08-05T14:00:00 | David Denton | kept | FY2025 adjusted EPS of $3.22 exceeded this mid-year raised range. |
| “We expect total company full year 2025 revenues to be in the range of $61 billion to $64 billion and full year 2025 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share” | Pfizer Inc., Q1 2025 Earnings Call, Apr 29, 2025 · 2025-04-29T14:00:00 | David Denton | kept | FY2025 landed at $62.6B revenue (within range) and $3.22 adjusted EPS (above the initial range). |
| “We now expect revenues in the range of $61 billion to $64 billion” | Pfizer Inc., Q3 2024 Earnings Call, Oct 29, 2024 · 2024-10-29T14:00:00 | David Denton | kept | Raised FY2024 revenue guide; the year closed at $63.6B, within the range. |
| “we expect adjusted diluted earnings per share of $2.45 to $2.65” | Pfizer Inc., Q2 2024 Earnings Call, Jul 30, 2024 · 2024-07-30T14:30:00 | David Denton | kept | Raised FY2024 adjusted EPS guide; the year finished at $3.11, well above after subsequent raises. |
Q&A pressure map
Question counts and firms are curator tallies; analyst coverage shown above.
| Topic | Questions | Firms | Pressure / response |
|---|---|---|---|
| COVID revenue trajectory and back-half derisking | 6 | Evercore ISI, Wells Fargo, Wolfe Research, Berenberg, TD Cowen | The most persistent line of questioning across the window. After the 2023 miss, analysts repeatedly tested how much COVID risk was baked into guidance; management's stock answer became that COVID is 'derisked' and seasonally back-half weighted. |
| Capital allocation, BD capacity and dividend safety | 5 | UBS, JPMorgan, Evercore ISI, BMO Capital Markets, Citi | Intensified by Starboard in late 2024 and again on the Q1 2026 call; analysts push on buyback timing, deal size and dividend durability, and management consistently defers buybacks while affirming the dividend. |
| Tariffs, MFN and drug-pricing policy | 5 | UBS, Cantor, TD Cowen, BofA, Jefferies | Dominated the 2025 calls. Analysts sought a quantified 2025-2026 policy impact; management repeatedly declined to size it, saying it was still under active discussion — a conservative non-answer rather than a clear evasion. |
| Obesity / Metsera program and data quality | 4 | JPMorgan, TD Cowen, Guggenheim, Leerink Partners | Skeptics questioned whether Metsera's data is differentiated versus incumbents and worth the contested acquisition; management defended diligence and monthly-dosing differentiation. |
| Oncology pipeline readouts (SV, ADC vs docetaxel) | 4 | Jefferies, Bernstein, Morgan Stanley, Leerink Partners | Analysts pressed on the second-line lung ADC bar; management conceded no ADC has yet beaten docetaxel there and pointed to a pending mid-year readout. |
Language shifts
Only language evidence verified against the referenced component is shown.
| Observation | Verbatim evidence | Call ID | Component |
|---|---|---|---|
| In 2024 management's register was defensive and credibility-focused after the COVID miss, repeatedly invoking caution. | “We know credibility is extremely important for us.” | 1875220311 | 52 |
| Dividend protection was cast in unusually emphatic terms during the post-miss period. | “The dividend is a sacred cow for us.” | 1875220311 | 57 |
| By late 2025 the tone toward competition turned combative, adopting aggressive new vocabulary around the Metsera contest. | “What they want is to catch and kill an emerging competitor” | 1961670320 | 11 |
| By Q1 2026 the language shifted to conviction about the post-cliff growth outlook, replacing hedged projections with 'clear line of sight.' | “Following the Vyndamax settlement, we now have a clear line of sight to a high single-digit 5-year revenue CAGR post-2028.” | 1991561932 | 3 |
The call history reframes Pfizer's debate from the 2023 COVID-credibility crisis to whether an enlarged pipeline and the Vyndamax reprieve can bridge the 2026-2028 patent cliff to renewed growth from 2029. Management has delivered on the beat-and-raise cadence it set for 2024-2025, which lends some weight to its post-2028 confidence, but the recurring, unresolved analyst pressure on buybacks, deal size and dividend durability signals the market is not yet taking that bridge for granted.